Biotech IPOs Rebound...But Where's BioRx?
1995 has witnessed a startling turnaround in the biotech public equity market, but while biotech IPOs haven’t reached these levels since the financing window of 1991-92, they don’t look like they used to. As the chart below illustrates, today’s biotech IPO investor tends to favor biodiagnostic companies and companies selling drug development services.
You may also be interested in...
Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.